Vanguard Group Inc Oncocyte Corp Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.25 - $15.6 $625 - $39,000	2,500 Added 0.06%	4,359,202 $1.39 Million
Q3 2022 Nov 14, 2022	BUY	$0.76 - $15.98 $7,730 - $162,548	10,172 Added 0.23%	4,356,702 $3.18 Million
Q2 2022 Aug 12, 2022	BUY	$0.86 - $1.53 $309,823 - $551,197	360,260 Added 9.04%	4,346,530 $3.91 Million
Q1 2022 May 13, 2022	BUY	$1.15 - $2.25 $104,114 - $203,701	90,534 Added 2.32%	3,986,270 $5.94 Million
Q4 2021 Feb 14, 2022	BUY	$2.04 - $3.59 $40,308 - $70,934	19,759 Added 0.51%	3,895,736 $8.45 Million
Q3 2021 Nov 12, 2021	SELL	$3.53 - $5.89 $116,733 - $194,776	-33,069 Reduced 0.85%	3,875,977 $13.8 Million
Q2 2021 Aug 13, 2021	BUY	$3.77 - $6.0 $14.7 Million - $23.5 Million	3,909,046 New	3,909,046 $22.4 Million

399K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $246M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.